The accuracy of pathological data for the prediction of insignificant prostate cancer by Katz, Betina et al.
  Universidade de São Paulo
 
2012-11
 
The accuracy of pathological data for the
prediction of insignificant prostate cancer
 
 
INTERNATIONAL BRAZ J UROL, RIO DE JANEIRO, v. 38, n. 6, pp. 760-768, NOV-DEC, 2012
http://www.producao.usp.br/handle/BDPI/33547
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Outros departamentos - FM/Outros Artigos e Materiais de Revistas Científicas - FM/MCG
ORIGINAL ARTICLE
760
Key words:
Prostate cancer; Prostate; 
Gleason score; Diagnosis
Int Braz J Urol. 2012; 38: 760-8
__________________
    
Submitted for publication:
February 14, 2012
__________________
    
Accepted after revision:
August 14, 2012
Introduction: The widespread screening programs prompted a decrease in prostate can-
cer stage at diagnosis, and active surveillance is an option for patients who may harbor 
clinically insignifi cant prostate cancer (IPC). Pathologists include the possibility of an 
IPC in their reports based on the Gleason score and tumor volume. This study determi-
ned the accuracy of pathological data in the identifi cation of IPC in radical prostatec-
tomy (RP) specimens.
Materials and Methods: Of 592 radical prostatectomy specimens examined in our la-
boratory from 2001 to 2010, 20 patients harbored IPC and exhibited biopsy fi ndings 
suggestive of IPC. These biopsy features served as the criteria to defi ne patients with 
potentially insignifi cant tumor in this population. The results of the prostate biopsies 
and surgical specimens of the 592 patients were compared.
Results: The twenty patients who had IPC in both biopsy and RP were considered real 
positive cases. All patients were divided into groups based on their diagnoses following 
RP: true positives (n = 20), false positives (n = 149), true negatives (n = 421), false ne-
gatives (n = 2). The accuracy of the pathological data alone for the prediction of IPC 
was 91.4%, the sensitivity was 91% and the specifi city was 74%.
Conclusion: The identifi cation of IPC using pathological data exclusively is accurate, 
and pathologists should suggest this in their reports to aid surgeons, urologists and 
radiotherapists to decide the best treatment for their patients.
INTRODUCTION
The detection of patients with nonpalpable 
prostate cancer has increased since the advent of 
prostate-specifi c antigen (PSA) screening. Modi-
fi ed prostatic biopsy schemes have also contribu-
ted to higher detection rates (1). Many of these 
earlier, smaller cancers are low volume (< 0.5 cm3), 
low grade and clinically insignifi cant tumors. Ap-
proximately one third of patients with stage T1c 
cancer have potentially clinically insignifi cant 
tumors, and approximately 5% of radical prosta-
tectomy (RP) patients have small cancers that are 
diffi cult to identify histologically (2).
 Epstein et al. initially created a set of four 
criteria to predict insignifi cant prostate cancer 
prior to defi nitive therapy: PSA density 0.1-0.15, 
low or intermediate cancer grade, core involve-
ment of less than 3 mm, and involvement of only 
one needle biopsy core. These criteria identifi ed 
Vol. 38 (6): 760-768,  November - December, 2012
The accuracy of pathological data for the prediction of 
insignifi cant prostate cancer
_______________________________________________
Betina Katz, Miguel Srougi, Luiz H. Camara-Lopes, Alberto A. Antunes, Luciano Nesrallah, Adriano 
Nesrallah, Marcos Dall’Oglio, Katia R. M. Leite
Laboratory of Medical Research - LIM55, Department of Urology, University of São Paulo Medical School 
(BK, MS, AAA, LN, AN, MD, KRML) and Laboratory of Surgical and Molecular Pathology - Sirio Libanes 
Hospital (BK, CL, KRML), São Paulo, Brazil
ABSTRACT         ARTICLE INFO_______________________________________________________________________________
761
IBJU | PATHOLOGICAL DATA FOR THE PREDICTION OF INSIGNIFICANT PROSTATE CANCER
79% of tumors with a volume < 0.5 cm3 that were 
organ confi ned and did not qualify as high-grade 
lesions at the time of RP (3).
 However, the Epstein criteria, which were 
later updated (4), are insuffi cient, and 20% of pa-
tients who fulfi ll these criteria may have unfavo-
rable pathological cancer characteristics at RP (5). 
The validity of these criteria has been questioned. 
Jeldres et al. demonstrated that the Epstein criteria 
may not be applicable to European men becau-
se prostate cancer was underestimated in 24% of 
these patients (1).
 The aim of this study was to assess the 
prediction of insignifi cant prostate cancer based 
on the biopsy fi ndings of patients who underwent 
RP and exhibited insignifi cant cancer. The biopsy 
features from these subjects were evaluated, and 
patients whose biopsies had similar parameters 
were selected. The biopsies were correlated with 
the respective RP specimens to identify the lesion 
characteristics and the clinical signifi cance of the 
tumor.
MATERIALS AND METHODS
 A total of 592 patients underwent trans-
rectal ultrasound-guided (TRUS) prostate biopsy 
followed by radical prostatectomy for prostate 
cancer from January 2001 to December 2010. A 
single surgeon (MS) treated all patients and a sin-
gle uropathologist (KRML) examined all biopsies 
and surgical specimens. The surgical specimens 
were fi xed in 10% buffered formalin, the entire 
surgical margin was stained with India ink, the 
left and right lobes were separated, 3 mm trans-
verse serial sections were taken from each lobe, 
and the entire gland was submitted for histolo-
gic examination. Sections of the bladder neck, 
prostatic apex, seminal vesicles, and pelvic lym-
ph nodes were also submitted to exam. The Gle-
ason score (GS) was used for histologic grading 
(6). The tumor volume was evaluated as described 
by Humphrey et al. (7). Briefl y, a grid was placed 
below the slides, on which the area involved by 
the tumor had been previously sketched out. The 
percentage of tumor on a slide was determined by 
dividing the number of squares involved by tumor 
by the number of squares occupied by the whole 
section on the slide. Tumor volume was defi ned 
as the mean percentage of tumor in the prostate 
gland (the percentage of tumor on each slide di-
vided by the number of slides from the prostate 
gland). Extraprostatic involvement was defi ned as 
tumor infi ltration of the adipose tissue, the neuro-
vascular plexus, or the parenchyma of the seminal 
vesicles. The TNM 2010 system was used for tumor 
staging and patients were classifi ed as pT2 when 
tumor was confi ned to the organ and pT3 when 
EPE or seminal vesicles were infi ltrated by tumor. 
PM was considered when tumor glands were inked 
with India ink.
 Twenty-two (3.7%) of the 592 patients 
exhibited insignifi cant tumor in their RP, which 
was defi ned as an organ-confi ned adenocarcino-
ma, Gleason score (GS) < 6 with no tertiary high 
grade Gleason pattern, and a tumor volume  0.5 
cm3 (Figure-1). The biopsies from these patients 
were analyzed, and twenty cases (91%) presented 
the following features: adenocarcinoma (GS) < 6, 
one to three positive cores that consisted of less 
than 50% tumor and a total percentage of positive 
fragments < 10%. These features, which are simi-
lar to the Epstein criteria regarding pathological 
fi ndings and are referred during the paper as “our 
criteria”, served as the parameters for the selection 
of patients with potentially insignifi cant prostate 
cancer. In order to evaluate the importance of pa-
thological fi ndings in defi ning these tumors, our 
criteria were purposely created based solely on the 
biopsy features and did not include PSA or any 
imaging method. These criteria were used to re-
view the biopsy and radical prostatectomy results 
and defi ne the sensitivity, specifi city, and positive 
and negative predictive value of these parameters 
for the identifi cation of insignifi cant prostate car-
cinoma in our population.
RESULTS
 Twenty-two (3.7%) of the 592 patients 
exhibited clinically insignifi cant prostate cancer 
in their RP with a mean GS of 5.9 (range 5 to 6) 
and a tumor volume less than 0.5 cm3 that was 
organ-confi ned. Twenty patients (91%) also had 
potentially insignifi cant prostate cancer in their 
biopsies. These biopsy features, which served as 
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our criteria mentioned above, exhibited a mean 
GS of 5.9 and mean positive cores of 6%. This 
group was considered real positive (Table-1). The 
remaining 2 patients (9%) had GS of 7 in the biop-
sy, 3 cores positive for tumor, a higher percentage 
of a single core (40% and 70%) and 4% and 6% 
positive cores (in 13 and 14 cores, respectively). 
We consider this group as false negative, since we 
would not expect them to have insignifi cant tu-
mor in the RP. The RPs of additional patients who 
exhibited similar prostate biopsy characteristics of 
the real positive group were re-examined. A total 
of 149 patients (26%) had biopsies that met our 
criteria and were characterized as probable IPC. 
The mean GS was also 5.9, the mean percentage 
of tumor in a single core was 23.3%, and the mean 
percentage of cores that were positive for tumor 
was 5.4% (range 1.5 to 10%), which represented 
one to two positive cores in a mean of 15 biop-
sies. However, their RPs revealed clinically sig-
nifi cant carcinomas, including patients with pT3 
disease (4.7%) as well as patients with interme-
diate and high grade tumor (56 patients with GS 
7 and 16 with GS > 7). This group was considered 
false positive, which means they could have been 
considered as having IPC based on their biopsy 
features, despite having tumor with adverse pa-
thological characteristics. The real negative group 
* 22 patients had clinically insignifi cant prostate cancer; however, 2 patients had unfavorable features in their biopsy.
Figure 1 - Selection of patients who had clinically insignifi cant prostate cancer in radical prostatectomy as well as features 
of insignifi cant tumor in biopsy.
592 Radical
Prostatectomy
Specimens
20 Patients*
Clinically Insignifi cant
Prostate Cancer
• Organ-confi ned disease
• Gleason Score < 6 with no
tertiary high grade pattern
• Tumor volume < 0.5cm3
From the remaining 572
patients, how many
patients had these
features in their biopsy?
Biopsy features
• Gleason score < 6
• Number of positive cores < 3
• Percentage of core
involvement < 50%
• Percentage of positive
cores < 10%
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Table 1 - Comparison between biopsy and RP of the patients regarding clinical signifi cance of the tumor.
Number of patients (%) Biopsy Radical Prostatectomy 1
20 (3.4%) insignifi cant insignifi cant Real Positive
149 (25.2%) insignifi cant signifi cant False Positive
2 (0.34%) signifi cant insignifi cant False Negative
421 (71.11%) signifi cant signifi cant Real Negative
1 Gold Standard
was composed of 421 men whose biopsy and RP 
revealed signifi cant prostate cancer. All patient 
data are detailed in Table-2.
The sensitivity of our criteria for the iden-
tifi cation of clinically insignifi cant prostate cancer 
in RP was 91% with 74% specifi city. The positive 
predictive value was only 12%, and the negative 
predictive value was 99.5%. Therefore, if our criteria 
were used to predict signifi cant cancer, the probabi-
lity of a patient exhibiting signifi cant cancer would 
be almost certain at level of accuracy of 91.4%.
DISCUSSION
 Several studies have questioned the effi cacy 
of diagnosing limited cancer by needle biopsy, and 
the possibility of predicting tumor extent at RP ba-
sed on biopsies. The applicability and validity of the 
criteria and nomograms that are commonly used to 
predict insignifi cant prostate cancer have also been 
discussed. The current study designed a set of novel 
criteria that were based on our own data and restric-
ted to morphological aspects without the conside-
ration of clinical stage or tumor markers. Although 
clinical fi ndings, such as PSA level and PSA density, 
were not used, the features of the biopsies from pa-
tients with insignifi cant tumors at RP were similar 
to the biopsy criteria in the literature, such as a GS 
< 6 and limited tumor extent on biopsy. The current 
study does not propose criteria or models for the 
prediction of insignifi cant tumor. Conversely, this 
study clarifi ed the use of precise morphological fi n-
dings of prostate biopsy in the identifi cation of in-
signifi cant prostate cancer.
 Our data for the prediction of organ-con-
fi ned tumors are consistent with the literature. 
Bastian et al. updated the Epstein criteria, which 
are the most widely used criteria for the prediction 
of clinically insignifi cant prostate cancer, and de-
monstrated concordance with pathologically or-
gan-confi ned disease and a favorable grade (GS 6) 
in 83.9% of patients (4). Although 91.6% of these 
patients had organ-confi ned disease, 7.6% had a 
GS of 7 or higher.
 The validity of the Epstein criteria has 
been questioned in European men. In a study that 
evaluated 366 patients who fulfi lled the contem-
porary Epstein criteria demonstrated a similar rate 
of organ-confi ned disease (91.7%). But the percent 
of patients with a GS of 7 was substantially hi-
gher; 24% of patients had a GS of 7 at RP, which 
yielded lower overall accuracy (76% vs. 84%) (1). 
Unfortunately, these authors did not mention the 
number of patients with clinically insignifi cant 
tumor at RP. According to our criteria, 95.3% of 
the tumors were organ-confi ned, but 48.3% were 
GS  7 (37.6% patients were GS 7 and 10.7% were 
GS 8 or 9), which is substantially higher than the 
reported rate in previous studies.
 Jeldres et al. argued that the differences 
between biopsy and radical prostatectomy with 
respect to GS contributed to the observed error 
rate of the Epstein criteria (1). A potential upgra-
ding of the GS occurs in 24.3% to 28.2% of pa-
tients (8,9). The grade assignment is also harder to 
predict because of the small amount of tumor that 
is analyzed on biopsy. High-grade prostate cancer 
is the most important predictor of prognosis (10) 
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even when the tumor is organ confi ned, and it 
is the most informative predictor of biochemical 
recurrence (11).
 Epstein et al. created their criteria to pre-
dict insignifi cant tumor in patients with stage T1c, 
and it accurately predicted 73% of insignifi cant 
tumor (3). The current study predicted only 12% 
of the clinically insignifi cant tumors, but our sam-
ples were not limited to stage T1c patients. Despi-
te this low positive predictive value, the negative 
predictive value was 99%, which indicated that 
ninety-nine percent of the tumors that were iden-
tifi ed as signifi cant and required active therapy 
were indeed signifi cant tumors. This result addres-
ses the concern of overdiagnosis, which occurs at 
a rate of approximately 56% (12,13).
 The retrospective assessment of biopsies 
from patients with insignifi cant or signifi cant tu-
mors at RP revealed that all of the parameters that 
are usually used to estimate tumor extent, such as 
the number of positive cores, maximal involve-
ment of a single core and the percentage of posi-
tive cores, were similar in both groups. These re-
sults suggest an absence of rules for insignifi cant 
tumor behavior on needle biopsy.
 Numerous diffi culties exist in the use of 
prostatic needle biopsies to predict limited can-
cer at RP, and even the smallest cancer focus on 
a needle biopsy does not guarantee a clinically 
insignifi cant tumor. Small amounts of carcinoma 
(total linear extent less than 3 mm) do not pre-
dict insignifi cant tumors (14,15). Patients who are 
diagnosed based on a single focus less than 3 mm 
(GS  6) have only a 30% chance of harboring an 
insignifi cant tumor (16). Samaratunga et al. exa-
mined 58 patients with a single minute focus of a 
GS 6 on biopsy, and only 10 patients (17%) had 
insignifi cant tumor at RP (17). Forty-eight patients 
had signifi cant tumor, 8 patients had extraprosta-
tic extension and 32% of the patients had a GS > 
6. These authors concluded that a minute focus 
of prostate cancer on a needle biopsy is not indi-
cative of insignifi cant carcinoma in most cases. 
Interestingly, this study was performed without 
PSA screening. However, these authors demons-
trated that a larger prostate size was signifi cantly 
correlated with potentially insignifi cant cancer. 
These patients likely presented earlier for PSA tes-
ting because of symptoms, and an elevated PSA 
level due to the benign enlargement might lead to 
biopsies at an earlier stage. Cupp et al. demonstra-
ted only an 8% risk of insignifi cant cancer using 
tumor volume at biopsy (14), which is similar to 
our results. The percentage of tumor extension in 
millimeters relative to the total extension of all of 
the cores was 5% and a GS less than 7.
 In contrast, Allan et al. evaluated 54 PSA-
-screened patients with limited adenocarcinoma 
(< 0.5 mm) on biopsy; the majority of these pa-
tients exhibited potentially insignifi cant cancer, 
but only one-third warranted defi nitive thera-
py (2). Potentially clinically insignifi cant tumors 
were present in 67% of the patients in this study, 
and 44% of these patients had small tumors at 
RP (less than 0.1 cc). These authors also repor-
ted that a PSA density cutoff of 0.15 or less was 
correlated with clinically insignifi cant tumor, and 
the association of these criteria with limited can-
cer on biopsy predicted patients with insignifi cant 
tumors with a greater than 80% accuracy.
 The Epstein criteria are not perfectly ac-
curate, but no alternatives for prediction of cli-
nically insignifi cant prostate cancer are available 
(1). Kattan et al. derived several nomograms for 
the prediction of pathologically confi rmed insig-
nifi cant prostate cancer with an accuracy of 64 
to 79% (18). However, this series included 13 to 
20% of Gleason patterns of 2 as part of the GS, 
which is much lower than the GS consensus from 
2005. Nakanishi et al. improved the accuracy of 
the existing tools to 73%, especially in patients 
with a single positive core at biopsy (19).
 Chun et al. developed a nomogram to pre-
dict the probability of insignifi cant prostate can-
cer in a cohort of 1132 men and revealed a pre-
dictive accuracy of 90% (5). However, a strikingly 
important proportion of patients who were quali-
fi ed with a high probability of insignifi cant tumor 
using the Chun et al. nomogram (63%) and the 
Kattan et al. nomogram (45%) harbored aggres-
sive prostate cancer at RP. Chun et al. concluded 
that the nomogram studies were similar to the ori-
ginal Epstein et al. criteria in their ability to pre-
dict pathologically confi rmed insignifi cant pros-
tate cancer. Clinicians may expect a 80% accuracy 
when organ-confi ned prostate cancer is predicted 
767
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or a 76 to 79% accuracy when pathologically con-
fi rmed insignifi cant prostate cancer is predicted.
 Do these data suggest that a signifi cant 
number of patients might be left undertreated? Is 
active surveillance a dangerous choice that could 
jeopardize the curability of prostate cancer in 
some men? The answer to these questions appears 
to be no.
 A review of active surveillance revealed 
that the majority of patients stay on active sur-
veillance, and once a patient requires active treat-
ment, that patient presents with curable prostate 
cancer (12). The detection of prostate cancer pro-
gression in a patient who is selected for active sur-
veillance remains a continuing challenge, and the 
PSA level remains important during the decision 
process. The progression of Gleason grade and the 
increased percentage of cancers per core are also 
indicators for the cessation of active surveillance.
 Duffi eld et al. have also studied the RP 
fi ndings of patients in whom active surveillance 
has failed (13). These authors relied solely on sub-
sequent biopsy pathology to determine progres-
sion, and more extensive disease was observed in 
surveillance biopsies during the fi rst 2 years of 
follow-up in the majority of cases.
 Despite their high accuracy rates, curren-
tly available models for the prediction of insigni-
fi cant prostate cancer are incorrect in 10 to 20% 
of cases. The addition of novel markers is required, 
and current imaging techniques, such as multipa-
rametric magnetic resonance, may have a poten-
tial role.
 Tumor location is problematic for sampling 
adequately. Anterior tumors are diffi cult to assess 
and sample clinically, and the amount of these tu-
mors in biopsies is lower than the amount of tumor 
from equivalently sized posterior tumors (20,21). 
These tumors appeared smaller on biopsy, but they 
were also undersampled. Takashima et al. analyzed 
the anatomical patterns of disease distribution in 
nonpalpable tumors and demonstrated that these 
tumors were localized predominantly in the ante-
rior half of the prostate at the apical to midprostate 
level (21). These authors suggested that additional 
cores from the anterior apical site could enhance 
the detection rate of prostate cancer. Miyake et al. 
evaluated the signifi cance of additional cores in the 
dorsal apex and demonstrated a signifi cant incre-
ase (9.3%) in the cancer detection rate, particularly 
for early stage disease (22).
In conclusion, we have shown that the 
biopsy data exclusively are accurate to diagnose 
IPC, and pathologist should suggest this possibili-
ty in their reports helping urologists, oncologists 
and radiotherapists to choose the better treatment 
for each patient.
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